Breaking News, Collaborations & Alliances

Navrogen, Lonza Enter Bio Production Deal

Sign agreement to use Lonza’s GS Gene Expression System for Navrogen’s anti-HIO targeting agents.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Navrogen and Lonza Pharma & Biotech have entered a licensing agreement for the production of Navrogen biotherapeutics using Lonza’s GS Xceed Expression System.   Navrogen recently announced funding to develop biotherapeutics targeting Humoral Immuno-Oncology (HIO) factors to reverse their inhibitory activity against the pharmacologic effects of antibody-based therapies. Navrogen’s biological drugs involve novel protein and antibody-based configurations. Lonza’s GS Xceed toolbox includes GS P...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters